Status of SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN)

Sánchez-Álvarez, J. Emilio; Fontán, Miguel Pérez; Martín, Carlos Jiménez; Pelícano, Miquel Blasco; Reina, Carlos Jesús Cabezas; Prieto, Ángel M. Sevillano; Melilli, Edoardo; Barrios, Marta Crespo; Heras, Manuel Macía; Pino, María Dolores del Pino y

doi:10.1016/j.nefroe.2020.04.002

Cited by 55 publications

(63 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ten articles from Medrxiv/Google Scholar were added, so 29 articles were included, of which 25 were observational studies, one was an interventional non-randomized study and three were RCT. These studies included 27 articles for hydroxychloroquine [ [14] , [15] , [16] , [17] , [18] , [19] , 23 , 24 , 36 , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] ] and 12 articles for hydroxychloroquine + azithromycin [ 18 , 36 , 41 , 42 , 47 , 48 , 50 , 51 , [57] , [58] , [59] , [60] ]. For chloroquine, after searching PubMed, Cochrane Review, Embase and Web of Science, 449 articles were identified.…”

Section: Resultsmentioning

confidence: 99%

“…Ten studies were conducted in the USA [ 15 , 18 , 23 , 41 , 42 , 49 , 50 , 53 , 56 , 58 ], four in Spain [ 16 , 17 , 44 , 57 ], seven in France [ 13 , 24 , 46 , 48 , 54 , 59 , 60 ], one in the UK [ 40 ], two in Italy [ 43 , 65 ], one in China [ 14 ], one in Brazil [ 51 ] and three in several other countries (USA, Canada, Italy and Spain) [ 39 , 47 , 52 ]. Twenty-two articles were published [ [13] , [14] , [15] , 17 , 18 , 24 , 39 , 41 , 43 , 44 , 46 , 47 , [49] , [50] , [51] , [52] , [53] , [54] , 56 , 57 , 59 , 60 , 65 ] and six articles were preprints [ 16 , 23 , 40 , 42 , 48 , 58 ]. Mean daily dose of hydroxychloroquine ranged from 333 mg/day to 945 mg/day.…”

Section: Resultsmentioning

confidence: 99%

“…Mean daily dose of hydroxychloroquine ranged from 333 mg/day to 945 mg/day. Few studies precisely described concomitant use of corticosteroids (see Supplementary material, Table S3 ) [ [15] , [16] , [17] , 44 , 48 , [50] , [51] , [52] , 65 ]. Only the RECOVERY trial precisely reported the use of dexamethasone (8% versus 9% in both arms) [ 40 ].…”

Section: Resultsmentioning

confidence: 99%

“…Among the observational studies, fourteen articles had a moderate or serious risk of bias [ [13] , [14] , [15] , [16] , [17] , [18] , 41 , 42 , 44 , [46] , [47] , [48] , 56 , 58 ] and eleven studies had a critical risk of bias [ 23 , 43 , 49 , 50 , [52] , [53] , [54] , 57 , 59 , 60 , 65 ]. Eleven observational studies did not report adjusted effect sizes to control confusion and selection bias [ 23 , 24 , 43 , 44 , 49 , 53 , 54 , 57 , 59 , 60 , 65 ]. Quality of studies was lowered by the lack of information about the assignment of treatment, the time between start of follow up and start of intervention, some unbalanced co-intervention with other antiviral and antibiotic drugs and imbalance between groups for confounders such as co-morbidities and age.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis

Fiolet

Guihur

Rebeaud

et al. 2021

Clinical Microbiology and Infection

263

207

View full text Add to dashboard Cite

Background Hydroxychloroquine or chloroquine with or without azithromycin have been widely promoted to treat coronavirus disease 2019 (COVID-19) following early in vitro antiviral effects against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Objective The aim of this systematic review and meta-analysis was to assess whether chloroquine or hydroxychloroquine with or without azithromycin decreased COVID-19 mortality compared with the standard of care. Data sources PubMed, Web of Science, Embase Cochrane Library, Google Scholar and MedRxiv were searched up to 25 July 2020. Study eligibility criteria We included published and unpublished studies comparing the mortality rate between patients treated with chloroquine or hydroxychloroquine with or without azithromycin and patients managed with standard of care. Participants Patients ≥18 years old with confirmed COVID-19. Interventions Chloroquine or hydroxychloroquine with or without azithromycin. Methods Effect sizes were pooled using a random-effects model. Multiple subgroup analyses were conducted to assess drug safety. Results The initial search yielded 839 articles, of which 29 met our inclusion criteria. All studies except one were conducted on hospitalized patients and evaluated the effects of hydroxychloroquine with or without azithromycin. Among the 29 articles, three were randomized controlled trials, one was a non-randomized trial and 25 were observational studies, including 11 with a critical risk of bias and 14 with a serious or moderate risk of bias. After excluding studies with critical risk of bias, the meta-analysis included 11 932 participants for the hydroxychloroquine group, 8081 for the hydroxychloroquine with azithromycin group and 12 930 for the control group. Hydroxychloroquine was not significantly associated with mortality: pooled relative risk (RR) 0.83 (95% CI 0.65–1.06, n = 17 studies) for all studies and RR = 1.09 (95% CI 0.97–1.24, n = 3 studies) for randomized controlled trials. Hydroxychloroquine with azithromycin was associated with an increased mortality (RR = 1.27; 95% CI 1.04–1.54, n = 7 studies). We found similar results with a Bayesian meta-analysis. Conclusion Hydroxychloroquine alone was not associated with reduced mortality in hospitalized COVID-19 patients but the combination of hydroxychloroquine and azithromycin significantly increased mortality.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis

Fiolet

Guihur

Rebeaud

et al. 2021

Clinical Microbiology and Infection

263

207

View full text Add to dashboard Cite

show abstract

“…We took a median value for the symptomatic rate of 69% following a variety of studies (see [6,21,23,[27][28][29]).…”

Section: (B) Parameter Determinationmentioning

confidence: 99%

Cost and social distancing dynamics in a mathematical model of COVID-19 with application to Ontario, Canada

Moyles

Heffernan

Kong

2020

Preprint

View full text Add to dashboard Cite

A mathematical model of COVID-19 is presented where the decision to increase or decrease social distancing is modelled dynamically as a function of the measured active and total cases as well as the perceived cost of isolating. Along with the cost of isolation, we define a healthcare cost and a total cost. We explore these costs by adjusting parameters that could change with policy decisions. We observe that minimum costs are not always associated with increased spending and increased vigilance which is due to the desire for people to not distance and the fatigue they experience when they do. We demonstrate that an increased in the number of lock-downs, each of shorter duration can lead to minimal costs. Our results are compared to case data in Ontario, Canada from March to August 2020 and details of extracting the results to other regions is presented.

show abstract

Clinical manifestations of COVID-19 infection in dialysis patients and protective effect of COVID-19 vaccine

Zhang

Chen

2023

Inflamm. Res.

View full text Add to dashboard Cite

Background and objective COVID-19 infection poses a special challenge to patients with dialysis patients. The purpose of this study was to evaluate the clinical manifestations of dialysis patients with COVID-19 and the protective effect of the vaccine. Methods We included 41 studies based on big data, mainly analyzing the clinical symptoms of dialysis patients with COVID-19, the proportion of severe patients before and after vaccination, and the humoral reaction of vaccine in the body. Results 6.1% to 35.7% of dialysis patients with COVID-19 developed respiratory distress symptoms and needed to be admitted to an intensive care unit for mechanical ventilation. The incidence and mortality of COVID-19 in dialysis patients before vaccination were 5.5% and 1.1%, respectively, and decreased to 4.5% and 0.6% in breakthrough infected patients. There was no statistical difference in serum conversion rates between dialysis patients and healthy controls, but the neutralizing antibody titer in the control group was 1922 (IQR 533 to 3186) AU/mL, and the neutralizing antibody titer in dialysis patients significantly decreased to 367 (IQR 171 to 1650) AU/mL ( P =0.046). Conclusions Dialysis is associated with an increased risk of severe COVID-19, and generally has a poor seroconversion response to vaccines. It also confirms the protective effect of vaccines on high-risk populations such as dialysis.

show abstract

Status of SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN)

Cited by 55 publications

References 13 publications

Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis

Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis

Cost and social distancing dynamics in a mathematical model of COVID-19 with application to Ontario, Canada

Clinical manifestations of COVID-19 infection in dialysis patients and protective effect of COVID-19 vaccine

Contact Info

Product

Resources

About